The Food and Drug Administration granted CLR 131, a targeted, molecular radiotherapy, a fast track designation. Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) could soon ...
Among the top stories in hematology/oncology last week were the FDA granting fast track designation to CLR 131 for the treatment of diffuse large B-cell lymphoma and a Q&A focusing on a virtual ...
Data showed durable clinical responses, including a 33% overall response rate (ORR) and 16.6% complete response (CR) FLORHAM PARK, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback